Maya Balakrishnan

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017–2018

Xiaotao Zhang, Natalia I. Heredia, Maya Balakrishnan et al. · PLoS ONE · 2021 · 109 citations · Full text

Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease

George Cholankeril, Jennifer R. Kramer, Jinna Chu et al. · Journal of Hepatology · 2022 · 95 citations · Full text

Metabolic Associated Steatohepatitis, Hepatology, Nonalcoholic Fatty Liver Disease +13

Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis

Zhensheng Wang, David Y. Graham, Anam Khan et al. · International Journal of Epidemiology · 2018 · 78 citations · Full text